GSK (GSK) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended the approval of depemokimab in two indications: as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids plus another asthma controller; as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK announces EMA CHMP recommended expanding indication of its RSV vaccine
- Blujepa approved by FDA as oral option for treatment of urogenital gonorrhea
- GSK price target raised to 1,500 GBp from 1,200 GBp at HSBC
- GSK announces GSK’277 received ODD from FDA to treat SCLC
- Ideaya disclosed termination of GSK license agreement